That dewy glow, like a cloudburst mist in the desert sky. Let your lit-from-within friends know they are seen. Theres even skincare for down there.

$50

Brought to you by MeCBD

Featuring Your Majesty CBD Cream, Pure Vitamin C Serum with CBD and CBD body butter, theMeCBD Holiday Beauty Faves package was made for the most glamorous person on your gift list. Whether theyve perfected the multi-step skincare routine, or simply aspire to CBD skin greatness, theyll enjoy the soothing, nourishing, and brightening ingredients of each organic product.

$49.99

If youve been keeping it cute and cuddly with someone, Heylos Loud Sensational Intimate Moisturizer might be the perfect gift to show them your appreciation. With lab-tested ingredients and a non-sticky formula, this lube is actually a great gift no matter what time of year. No bae in sight? Go ahead and treat yourself to this silky, CBD silicone-based delight.

$15.99

(Alex Manning/Leafly)

Amber has a wide range of CBD skin products that can be mixed and matched for a personalized holiday gift. Whatever you choose, dont miss the CBD face masque, infused with rosemary and black licorice to help keep skin aglow, even in the dreariest of winter months. Skincare lovers will squeal when they realize the mask comes in two convenient pieces so that it can hit every contour of their gorgeous faces.

$51

Brought to you by MeCBD

You cant always be sure that your faves can make it to the spa, but you can bring the spa to them with the MeCBD Holiday Spa Faves package. This package features CBD massage oil, CBD apple stem cell face cream formulated to reduce lines and wrinkles, and a Dead Sea mud mask infused with CBD to help revitalize worn-out, dull skin cells. Its the spa in a bag (or delivery box) that your hard-working loved ones deserve.

$48

Herbivores Emerald Deep Glow Oil contains CBD and adaptogens that leave faces looking dewy and rejuvenated. Its the perfect antidote for skin fighting the effects of dry winds and stale airplane air, so your faves can stay flawless no matter where they go. And remember, we wont tell if you get the full size for yourself, and the minis for your favorite jet-setters.

$80

Made with wild lavender, black currant seed oil, and frankincense, you dont have to be one of the Three Wise Men to know that this face serum is packed with heavy-hitting botanicals. Khus Khus Sen serum blends both Ayurvedic and Western ingredients to tap into the life cycle of cells and help with acne, inflammation, fine lines, and balance.

Leafly is the worlds largest cannabis information resource, empowering people in legal cannabis markets to learn about the right products for their lifestyle and wellness needs. Our team of cannabis professionals collectively share years of experience in all corners of the market, from growing and retail, to science and medicine, to data and technology.

Read the rest here:
Leafly's Holiday Gifts: For the skin you're in - Leafly

Skin Stem Cells Comments Off on Leafly’s Holiday Gifts: For the skin you’re in – Leafly | December 6th, 2019

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science

Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (Novadip or the company), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series of presentations at the 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) taking place in Marseille, France, from 4-7 December 2019.

Dr Denis Dufrane, Chief Scientific Officer and co-founder, Novadip, commented: The findings that will be presented at IFATS highlight the capabilities of Novadips 3-dimensional, scaffold-free extracellular matrix (ECM) technology platform utilizing adipose-derived stem cells (ASCs) to generate product candidates to address critical size bone and skin reconstruction, as well as our manufacturing capabilities and expertise. We look forward to progressing our clinical programmes and generating further data in support of our unique platform as we look to address hard and soft tissue reconstruction for patients who have limited or no treatment options.

Novadip will deliver five oral presentations and one video presentation. Details of the presentations and short summaries are below.

Genetic stability assessment in bone tissue-engineered productsCline Pierard, oral presentation #8 (abstract 1395), 5 December 2019, 8:38 am CET

The presentation will discuss the different analytical approaches to predict the genetic behavior over the entirety of the manufacturing process for the companys product candidates for bone reconstruction.

A scaffold-free graft for large critical size bone defect: preclinical evidence to clinical proof of conceptSophie Veriter, video presentation #V5 (abstract 1363), 5 December 2019, 2:48 pm CET

The session will discuss how the scaffold-free 3D-graft (comprised of ASCs) plays a major role promoting ASCs engraftment and to induce osteogenesis in a fibrotic environment and promote bone fusion in a critical-sized bone defect.

The in vivo immunogenicity of a human 3D scaffold-free tissue engineered product for bone reconstruction: a xenogenic modelGatan Thirion, oral presentation #30 (abstract 1382), 5 December 2019, 4:30 pm CET

Detail will be provided on how the human scaffold-free 3D approach, in a xenogenic model, can elicit a specific anti-human immune response but can maintain the potential of in vivo osteogenicity.

An allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro development to in vivo proof of conceptSophie Veriter, oral presentation #88 (abstract 1317), 6 December 2019, 5:50 pm CET

The presentation will discuss how the scaffold-free approach with the allogenic 3D-graft (derived from ASCs) demonstrated safety and efficacy in a stringent xenogenic model of hyperglycemic and ischemic deep-thickness wound.

Allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro characterization and in vivo biocompatibilityValrie Lebrun, oral presentation #90 (abstract 1341), 6 December 2019, 6:06 pm CET

The presentation will provide an overview on how the allogenic scaffold-free 3D-graft improves ASC bioactivity for the angiogenesis and in vivo remodeling by the specific ECM-proteins of wound healing.

Monitoring of cell culture conditions and early prediction of the quality of an osteogenic cell-based medicinal productAnas Namur, oral presentation #136 (abstract 1392), 7 December 2019, 2:44 pm CET

The session will describe how cellular metabolism was studied throughout the companys manufacturing process to better understand the physiology of the proliferative and differentiated cells and subsequently develop predictive tests focused on critical attributes of the final product.

To view the full abstracts, please follow this link.

The full list of abstracts can be found here. Further information on IFATS is available here.

Ends

Notes to editors

Novadip Biosciences

Novadip Biosciences is a clinical stage biopharmaceutical company leveraging its unique 3D tissue regeneration technology platform to generate multiple product candidates to address hard and soft tissue reconstruction for patients who have limited or no treatment options. The companys proprietary 3M3 platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly-specific growth factors and miRNA to mimic the physiology of natural healing and creates a range of products that address specific challenges in tissue regeneration. Novadips initial focus is on critical size bone reconstruction and its lead program is in development for a rare pediatric orthopedic disease. The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects. For more information, visit http://www.novadip.com .

For further information, please contact:

Novadip Biosciences

Jeff Abbey

Chief Executive Officer

+32 (10) 779 220

info@novadip.com

For media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Angela Gray

+44 (0) 20 3709 5700

novadip@consilium-comms.com

Read more:
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science - Financialbuzz.com

Skin Stem Cells Comments Off on Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science – Financialbuzz.com | December 6th, 2019

New research at the University of Barcelona (UB) found the first genetic evidence that humanity has self-domesticated.

The team found a network of genes involved in the evolution of human face structure and prosociality in modern humans which is absent in the Neanderthal genome. This suggests that our ancestors preferred to hang out and mate with friendlier and more cooperative companions over less-cooperative, more aggressive ones. In effect, this amounted to selective pressure for prosocial behavior over time, meaning that we domesticated our own species.

Certain anatomical, cognitive, and behavioral traits of modern humans chief among them docility and a fragile facial structure are hallmarks of the domestication process. This led to the idea of human self-domestication being developed all the way back in the 19th century, the team explains. However, we lacked the tools to confirm that this process took place (i.e. that theres genetic evidence for it).

The study builds on the teams previous research that looked into genetic similarities between humans and domesticated animals. Now, the team went one step further and looked for genetic evidence for self-domestication in neural crest cells. This is a population of cells that have a major role to play in the early development of vertebrate embryos by differentiating into more specialized cells.

A mild deficit of neural crest cells has already been hypothesized to be the factor underlying animal domestication, explains co-author Alejandro Andirk, a Ph.D. student at the Department of Catalan Philology and General Linguistics of the UB.

Could it be that humans got a more prosocial cognition and a retracted face relative to other extinct humans in the course of our evolution as a result of changes affecting neural crest cells?

In order to test their hypothesis, the team focused on Williams syndrome disorder, a human-specific neurodevelopmental disorder caused by a deficit of neural crest cells as the embryo develops. It is characterized by mild to moderate intellectual disability or learning problems, unique personality characteristics, distinctive facial features, and cardiovascular problems.

The researchers used in vitro models of Williams syndrome (stem cells derived from the skin of patients with this syndrome). After poking around, they found that the BAZ1B gene, conveniently located in the region of the genome associated with Williams syndrome, is responsible for controlling the behavior of neural crest cells. If this gene was under-expressed, it led to reduced migration of these cells; higher expression levels led to greater neural crest migration. Then, they compared this gene to its equivalent in samples of archaic (i.e. extinct) and modern (i.e. our ancestors) human genomes.

We wanted to understand if neural crest cell genetic networks were affected in human evolution compared to the Neanderthal genomes, says Cedric Boeckx, ICREA professor at the Department of Catalan Philology and General Linguistics.

Differences in the BAZ1B gene between archaic and modern humans led to a high frequency of mutations in that accumulated over time in modern humans but not in any of the archaic genomes currently available. The team says this points to BAZ1B as being an important reason our face is so different when compared with our extinct relatives, the Neanderthals.

In the big picture, it provides for the first-time experimental validation of the neural crest-based self-domestication hypothesis, Boeckx adds.

The paper Dosage analysis of the 7q11.23 Williams region identifies BAZ1B as a major human gene patterning the modern human face and underlying self-domestication has been published in the journal Science Advances.

Read this article:
We have the first genetic evidence of human self-domestication - ZME Science

Skin Stem Cells Comments Off on We have the first genetic evidence of human self-domestication – ZME Science | December 6th, 2019

Stromal vascular fraction skin treatment is a type of stem cell therapy based on isolation of adipose tissue during liposuction or lipo-aspiration procedures of patients own body. In stromal vascular fraction treatment isolation of tissue contains fat cells, blood cells, and endothelial cells, as well as a large fraction of adipose-derived mesenchymal stem cells which provides regenerative properties and have positive anti-aging properties. A stromal vascular fraction is considered as a personalized stem cell therapy and effective tropical or injectable treatment.

With increasing age, regenerative and repair properties of skin are less effective due to decrease in stem cell count, and therefore, stromal vascular fraction treatment contains stem cell provides a boost in repair and maintenance mechanism of the skin leaving smooth, healthy, radiant skin. Stromal vascular fraction is a naturally occurring stem cell found in bundles of adipose tissues and are the primary source of growth factors along with macrophages and other cells. Due to the presence of growth factors, the stromal vascular fraction is utilized to decrease inflammation present in many diseases. A stromal vascular fraction is adopted in the treatment of rheumatoid arthritis, joint replacement, osteoarthritis, diabetes, Crohn's disease, and others.

Stromal Vascular Fraction Market: Overview

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/2376

Stromal vascular fraction is a combination of adipose-derived stromal cells (ADSCs), endothelial cells (ECs), endothelial precursor cells (EPCs), smooth muscle cells, macrophages, pericytes, and pre-adipocytes in the aqueous state. Stromal vascular fraction is advantageous over alternative medical treatments as SVF has the ability to regulate patients own system with the main focus on cell repair and regulation of defective cells. Stromal vascular fraction is a promising field for disease prophylaxis and currently are in clinical trials.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on: Market Segments Market Dynamics Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies involved Technology Value Chain

Stromal Vascular Fraction Market: Segmentation

Request Report Methodology at https://www.xploremr.com/connectus/request-methodology/2376

The globalstromal vascular fraction marketcan be segmented on the basis of type of therapy, end-user, and region.

By Therapy Type SVF Isolation Products Enzymatic Isolation Non-enzymatic Isolation Automated POC Devices SVF Aspirate Purification Products SVF Transfer Products

By End-user Hospitals Specialty Clinics Stem Cell Banks/Laboratories Others

By Application Cosmetic Soft-tissue Orthopedic Others

By Region North America Latin America Europe Asia Pacific (APAC) South Korea Middle East and Africa (MEA)

In its last part, the report offers insights on the key players competing in the global market for stromal vascular fraction. With detailed profiling of each of the key companies active on the competitive landscape, the report provides information about their current financial scenario, revenue share at a global level, development strategies, and future plans for expansion. Strategic collaborations, mergers, and acquisitions have also been considered as a key strategy among a majority of leading companies in the market.

Buy Full Report at https://www.xploremr.com/cart/2376/SL

Go here to read the rest:
Stromal Vascular FractionMarket Estimated to be Driven by Innovation and Industrialization - The Market Expedition

Skin Stem Cells Comments Off on Stromal Vascular FractionMarket Estimated to be Driven by Innovation and Industrialization – The Market Expedition | December 6th, 2019

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

Read the original post:
A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives - Economic Times

Skin Stem Cells Comments Off on A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives – Economic Times | December 6th, 2019

(MENAFN - iCrowdNewsWire) Dec 5, 2019

Cardiac failure is an insidious disease with the mortality rate as high as that of cancer around the globe. Heart failure affecting at least 26 million people worldwide in 2017 and is increasing in prevalence. The only medical treatment for heart failure is cardiac transplantation, although the shortage of donor poses a serious problem. Cell transplantation therapy with regenerative cardiomyocytes is the only solution to minimize the higher mortality rates, which requires detailed information at the level of individual cardiomyocytes. Spinning disk confocal microscopy has emerged as a new high-tech method in cardiovascular medicine for exploring the stem cells for regenerating damaged organs. This innovative microscopic technology can be used to create 3D images of the structures within living cells. Higher-efficiency imaging at lower laser powers includes less photobleaching and phototoxicity, yet cost-effective than other confocal microscopes which are the prominent features of the spinning disk confocal microscopes (SDCM). Furthermore, technological advancements in microscopy and increasing spending on the research & development are the key factors fueling the spinning disk confocal microscope market share.

The global spinning disk confocal microscope market size was valued at $245 million as of 2018 and is expected to grow with a CAGR of 3.6% throughout the forecast period 2019-2025.

Extensive Usage of Spinning Disk Confocal Microscope in the Evaluation of Various Eye Diseases

Spinning disk confocal microscope is an imaging technique which eliminates out-of-focus light efficiently and improves the image contrast, making it easier to resolve small and dim structures in the living cell. This technique is ideal for imaging poor signals at high magnification and provides prolonged life imaging with minimal photodamage. SDCM is widely used in the evaluation of various eye ailments and is predominantly useful for imaging, identification, and detailed analysis of cornea cells. Cataract accounts for the world's leading vision impairment cause, affecting approximately 12.6 million people and 52.6 million people who live with severe to mild blindness worldwide. The confocal microscope helps to provide valuable information about wound healing in the postsurgical cornea, especially after keratorefractive and transplant surgery, which in turn, creates a huge opportunity for the growth of the spinning disk confocal microscope market share. Besides, in the pharmaceutical industry, increasing usage of this confocal microscopy in the classification of systems such as tablets, film coatings and colloidal systems, which in turn, spur the growth of the spinning disk confocal microscope market size.

Application of Spinning Disk Confocal Microscopy in Bio-imaging

Confocal microscopy allows the analysis of specimens without physical sectioning when these specimens are fluorescently labeled, then more color differentiation is possible. Besides, it allows the 3D reconstruction of the live cells and organisms. For instance, researchers of the State University of New York Downstate Medical Center have found that hypoxia, the condition of lack of oxygen in the body or region of the body tissues to sustain bodily functions is because of abnormal blood flow. This, in turn, is responsible for half of the seizure-related neuronal degeneration cases in epilepsy. Consequently, the microscopic technique enables the researchers to detect abnormality in the vasodynamics of brain. Instances as such are increasing the demand for the spinning disk confocal microscope market in bio-imaging.

North America Holding Major Share of the Spinning Disk Confocal Microscope Market

North America generated 34.4% of the spinning disk confocal microscope market global revenue in 2018. Growing adoption of the confocal microscope in living cell imaging, increasing application in dentistry, and government funding and policies for medical research are key factors triggering the growth of the spinning disk confocal microscope market in this region. For instance, as part of the 2019 budget, Canadian government has decided to spend approximately $4 billion on basic medical research and this funding is given to The Stem Cell Network, a non-profit organization in Ottawa which is active into clinical applications research. Also, Genome Canada, a non-profit organization in Ottawa which supports genomic research, will get about $77 million from the government for medical research. Thus, these increasing investments in research activities is boosting the North American spinning disk confocal microscope market.

Life Sciences Observing Lucrative Opportunities in the Global Spinning Disk Confocal Microscope Market

The application segment that will be creating the most lucrative opportunities for the spinning disk confocal microscope market is life sciences. This application segment is projected to grow at a CAGR of 32.3% through to 2025. To observe the internal workings of cellular processes in the living cells, this procedure is widely used by researchers in life science. Spinning disk confocal microscope use lower light levels and provide accurate cell physiology through real-time image acquisition. Thus, the cell study is aiding the growth of the life sciences segment in the global spinning disk confocal microscope market.

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=18554

The Major Players in the Spinning Disk Confocal Microscope Market :

Prominent players in the spinning disk confocal microscope market include Bruker Corporation, Confocal.nl, Leica Microsystem, Nikon Corporation, Olympus Corporation, and ZEISS Group.

Bruker Corporation, an American-based scientific instruments manufacturer for molecular and materials research has launched its high-speed Atomic Force Microscopy (AFM) system for life science microscopic applications on Jan 29, 2019. AFM features advanced bio-imaging with high speed and high resolution. These properties of the AFM system can provide researchers to perform experiments on individual cells and allow Bruker to follow dynamic processes on cellular and molecular levels in real-time. Secondly, Confocal.nl, Dutch-based microscopes manufacturer has launched new Re-scan Confocal Microscopy (RCM) modules on April 10, 2019. This new module features integrated optimized de-convolution and high scan speed.

Mergers and acquisitions are the other key strategies adopted by the players to stay ahead of their competitors. Bruker Corporation, an American-based scientific instruments manufacturer for molecular and materials research has announced its acquisition with Hain Lifescience GmbH, German-based molecular diagnosis systems developer on Aug 24, 2018. With this acquisition, Bruker has expanded its capabilities in microbial and viral pathogen detection and offering solutions for human genetic diseases. Such mergers and acquisitions aid the market players to expand their geographical boundaries and accentuate their footprint into the global spinning disk confocal microscope market.

Related Reports:

Microscopy Devices Market

https://www.industryarc.com/Report/116/Microscopy-Devices-Market.html

Surgical Microscopes Market

https://www.industryarc.com/Report/18476/surgical-microscopes-market-research-report-analysis.html

About IndustryARC:

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to[email protected]to discuss more about our consulting services.

MENAFN0512201900703403ID1099375804

Continued here:
Spinning Disk Confocal Microscope Market Growth Fueled by Reviving Techniques to Treat Heart Failure with Cardiac Regenerative Medicine - MENAFN.COM

Cardiac Stem Cells Comments Off on Spinning Disk Confocal Microscope Market Growth Fueled by Reviving Techniques to Treat Heart Failure with Cardiac Regenerative Medicine – MENAFN.COM | December 6th, 2019

Scientists now have the ability to collect massive amounts of data on lifes most fundamental processes, such as the intricate choreography whereby a handful of embryonic stem cells give rise to trillions of specialized cells throughout the human body. But data doesnt always translate into knowledge unless the relationship of recorded data points can be presented in accurate, meaningful and visible ways.

The lab of Yales Smita Krishnaswamy, associate professor of genetics and computer science, has developed a new algorithm called PHATE that overcomes many of the shortcomings of existing data visualization tools, which are more susceptible to noise and distortion in the relationship of data points.

The panel above shows how PHATE visualizes the differentiation of human embryonic stem cells into neuronal cells, neural stem cells, cardiac cells, and endothelial cells, as compared to the visualizations created by three other technologies.A cleaner, more detailed representation is helpful, for example, for generating promising new hypotheses.

The researchers work is described Dec. 3 in the journal Nature Biotechnology.

Here is the original post:
PHATED to be: Yale researchers give shape to big data - Yale News

Cardiac Stem Cells Comments Off on PHATED to be: Yale researchers give shape to big data – Yale News | December 6th, 2019

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the Market CLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @ CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Report for more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Here is the original post:
Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description

Cardiac Stem Cells Comments Off on Stem Cell Therapy Market Robust pace of Industry during 2017-2025 – News Description | December 6th, 2019

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, we would be focusing on the pre-clinical, manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. This Congress event will be held on 10th and 11th March 2020 in London -UK

Since the past three editions of Bioprocessing of Advanced Cellular Therapies and Regenerative Medicine, MarketsandMarkets aims to provide demonstrative approach to the latest developments in technologies of bioprocessing of cellular therapies.

What to expect:

The 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine would be concentrating on the pre-clinical, manufacturing, clinical and regulatory facets of cell therapies and regenerative medicine. The prime importance would be given on discussing topics such as tissue engineering, car-T cell-based immunotherapies, automated manufacturing, allogeneic therapies, from challenges in supply chain management and regulatory concern, point of view.

The conference will be useful for all the respective stakeholders of Advanced Cellular Therapies, majorly Pharma/Biotech delegates, Solution provider Delegates and Academic Delegates. The event will host VPs, directors, managers, leaders, engineers, scientists, academic heads, students which will boost the networking capacity of the attendees.

Download Agenda at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/

Conference Agenda:

The two-day conference will have a list of agenda:

Key Pointers 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

Conference Registration

Lets get you sorted! Choose which applies best to you @ https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/register

Read the original post:
MarketsandMarkets - 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Hitz Dairies

Cardiac Stem Cells Comments Off on MarketsandMarkets – 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress – Hitz Dairies | December 6th, 2019

Abstract

IFN- produced by T cells directly induces intestinal stem cell death upon inflammation-induced intestinal injury (see the related Research Article by Takashima et al.).

Intestinal regeneration upon tissue damage is fueled by intestinal stem cells (ISCs) residing in the crypt bottom of the epithelium and marked by the gene Lgr5 (1, 2). There is growing evidence that tissue repair is at least partially mediated by a regenerative inflammatory response (3, 4). How inflammation-induced intestinal injury influences ISCs and their microenvironment (stem cell niche) remains poorly understood. In this issue of Science Immunology, Takashima et al. (5) explore the changes in the ISC niche in vivo upon T cellmediated injury as a model of graft-versus-host disease (GVHD) and in vitro using organoid T cell cocultures. Although earlier studies already implicated interferon- (IFN-) as a negative regulator of intestinal epithelial homeostasis (68), Takashima et al. now demonstrate that IFN- directly acts on ISCs by triggering apoptosis.

In an allogeneic bone marrow transplant (BMT) model, Takashima and colleagues found that ISC numbers per intestinal crypt were markedly reduced in mice receiving bone marrow alone or bone marrow and T cells when compared with normal control mice. While the ISCs in the mice receiving only bone marrow recovered 7 days later, the ISC numbers remained reduced in those mice also transplanted with donor T cells. Of note, Paneth cell numbers were also reduced after ISC depletion. The numbers of organoids established from the intestines of mice 10 days after BMT recovered back to that of control mice, whereas the organoid forming capacity from crypts of mice after combined transplantation of bone marrow and T cells remained significantly lower. Similar in vivo and in vitro results were obtained when autoreactive T cells were transplanted, pointing to a common feature of T cellmediated intestinal injury.

As seen by three-dimensional confocal microscopy, intraepithelial T cells (CD3+ IELs) preferentially localized to the villus region, whereas lamina propriaassociated T cells (CD3+ LPLs) were equally distributed along the crypt-villus axis of control mice (Fig. 1A). Conversely, mice receiving bone marrow and allogeneic T cells showed a progressive increase in the density of both CD3+ LPLs and CD3+ IELs in the crypt region.

To identify signaling molecules that cause the loss of ISCs in this model, Takashima and colleagues performed several elegant murine and human epithelial organoid coculture experiments. Murine nave allogeneic T cells did not impair murine intestinal organoid numbers, whereas alloreactive T cells effectively reduced organoid numbers. Likewise, human allogeneic cytotoxic T cells robustly inhibited human intestinal organoid forming efficiency. Even bead-activated autologous T cells suppressed human intestinal organoid growth. The authors then proceeded to screen for potential pathways mediating cytotoxicity. Organoids cocultured with T cells in the presence of antiIFN- neutralizing antibodies showed normal growth. Although IFN- receptor (IFN-R)depleted T cells were still able to affect organoid viability, IFN-Rdepleted organoids were resistant to T cellmediated killing. Organoid toxicity by IFN- was also observed in the absence of T cells. Live imaging confirmed the progressive ISC depletion upon organoid exposure to IFN-. Treatment of organoids with the immunosuppressive JAK1/2 inhibitor ruxolitinib robustly preserved numbers of both organoids and ISCs in the presence of IFN-, irrespective of whether the organoids were cultured alone or together with T cells. The authors additionally demonstrated that JAK1-depleted organoids are resistant to IFN- treatment. Further downstream, ruxolitinib prevented STAT1 phosphorylation by IFN- in intestinal crypts, and, in line, STAT1-depleted organoids were resistant to growth suppression in response to IFN- treatment.

IFN-treated organoids showed reduced expression of ISC marker genes. ISCs underwent apoptosis in vitro in a direct response to IFN-. Next, the authors confirmed in vivo that ISC numbers did not change upon transplanting allogeneic bone marrow and T cells when treating mice with IFN- neutralizing antibodies. Likewise, ruxolitinib treatment protected ISCs from T cellmediated killing in vivo. Donor T cells, particularly T helper 1 cells, were activated and IFN-+. Transplanting IFN-depleted allogeneic T cells robustly reduced the ISC loss and allowed epithelial cell proliferation to increase.

Takashima and colleagues lastly investigated whether IFN- directly induces ISC apoptosis. Using tissue-specific depletion of IFN-R1, the authors found that epithelial loss of the receptor protects from the immune-mediated GVHD phenotype. IFN-R1 is expressed by both ISCs and Paneth cells, the epithelial component of the ISC niche (9). However, Paneth celldeficient organoids remained sensitive to both IFN- and allogeneic T cellmediated cytotoxicity. Likewise, T cells were able to reduce the number of organoids containing IFN-R1deficient Paneth cells, whereas organoids containing IFN-R1deficient ISC were protected from cytotoxicity. The authors demonstrated in further experiments that IFN- directly induces ISC apoptosis independent of Paneth cells (Fig. 1, B and C).

The study by Takashima et al. extends our knowledge on signaling between ISCs and immune cells, identifying ISCs as direct targets of IFN- secreted by T cells in immune-mediated intestinal damage (as caused by GVHD). In the 2015 study by Lindemans et al., this group already identified that interleukin-22 (IL-22) secreted by group 3 innate lymphoid cells (ILC3s) directly stimulates ISCs to proliferate and regenerate the intestinal epithelium upon inflammation-induced intestinal injury (4). Modulating the effects of T cellderived IFN- on ISC, for instance, by suppressing JAK/STAT signaling via ruxolitinib treatment, may provide a new therapeutic avenue to reducing GVHD-induced damage of the intestinal epithelium (10).

(A) ISCs maintain adult homeostasis of the intestinal epithelium. T lymphocytes patrol the intestine. (B) Takashima et al. show that in GVHD as modeled by BMT and aberrant activation of T lymphocytes, T cellderived IFN- directly acts on ISCs and induces apoptosis via JAK/STAT signaling. (C) Disease progression results in marked intestinal damage due to loss of ISCs and their niche.

Acknowledgments: Funding: K.K. is a long-term fellow of the Human Frontier Science Program Organization (LT771/2015). Competing interests: H.C. and K.K. are named inventors on patents or patents pending on Lgr5 stem cellbased organoid technology.

Follow this link:
IFN-: The T cell's license to kill stem cells in the inflamed intestine - Science

Bone Marrow Stem Cells Comments Off on IFN-: The T cell’s license to kill stem cells in the inflamed intestine – Science | December 6th, 2019

COLOGNE, Germany, Dec. 5, 2019 /PRNewswire/ -- Cellex has opened a new Cell Manufacturing Plant in Cologne, Germany that will be the focal point for the production of innovative cell therapy products (e.g. CAR-T cells) as targeted treatments for different types of cancers and other diseases. The new facility has doubled the company's manufacturing capacity. Reasons for the expansion include the rising global demand and worldwide bottlenecks in production, as well as a considerable amount of promising research on new treatment approaches for various types of cancer. With this expansion, Cellex has laid the groundwork to provide comprehensive support to patients all over the world who are dependent on new therapies for the treatment of serious diseases. The facility offers more than 800 square meters of floor space and contains a clean room laboratory and other rooms for manufacturing and quality control.

At the new Cell Manufacturing Plant, advanced therapy medicinal products (ATMPs) such as CAR-T cells are produced using state-of-the-art methods including magnetic selection, cell purification, cryopreservation and cell-based efficacy tests. Other services include long-term cryo-storage for ATMPs. Through international partnerships, Cellex is already operating at a global level and is expecting to see growth in worldwide demand for its products. In addition to specialized expertise in manufacturing cell therapy products, the company also operates collection centers for stem cell and bone marrow donations as well as a CellCommunity for the donation of cells to science and research all over the world.

The Cellex Group was founded in 2001 with a primary focus on the collection of stem cells and bone marrow. Today, the Cellex Collection Center is the world's largest and most experienced collection center for allogeneic blood stem cell and bone marrow donations. Furthermore, Cellex has grown into an important full service provider for other companies in the production of innovative cellular therapy products (e.g. CAR-T cells). Since 2014, the company has been working on the development of its own innovative CAR-T cells and bispecific antibodies for the treatment of cancer in collaboration with its Dresden-based affiliate, GEMoaB.

During the opening ceremonies, Prof. Dr. Gerhard Ehninger, founder and owner of Cellex, pointed to the encouraging possibilities offered by CAR-T cell therapies being developed by Cellex. "Battling cancer with CAR-T cells specifically targeted against tumor cells is one of the most promising treatment approaches today. However, CAR-T cells developed so far harbor various risks, such as excessive cytokine release or the development of resistances. Therefore, we are now collaborating with our affiliate, GEMoaB, to develop new platforms that are easier to control such as bispecific antibodies or UniCAR cells, which are currently undergoing initial testing."

About Cellex

Cellex wants to help people suffering from serious diseases through stem cell donations, but also through innovative treatment options. Cellex develops, tests and establishes new therapy approaches for people with cancer. These new cutting-edge medicines are manufactured by Cellex at the company's Cell Manufacturing Plant.

Story continues

See original here:
Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer - Yahoo Finance

Bone Marrow Stem Cells Comments Off on Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer – Yahoo Finance | December 6th, 2019

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 Process B received investigational therapy. RP-L102 is the Companys lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA).

The initiation of Rockets first Phase 2 trial is an important milestone for the company as well as patients throughout the world battling FA, said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Head of Development of Rocket. With the recent feedback received from the FDA and EMA of MMC-resistance as the primary endpoint, we are optimistic about the prospect of benefiting patients and, if the data are positive, working towards BLA and MAA submissions.

The registrational package will include twelve patients from the U.S. and EU, two from the U.S. Phase 1 study and 10 additional patients from the global Phase 2 study (NCT04069533). Patients will receive a single intravenous infusion of RP-L102 that utilizes fresh cells and Process B which incorporates a modified stem cell enrichment process, transduction enhancers, as well as commercial-grade vector and final drug product. Improved mitomycin-C (MMC) resistance in bone marrow colony forming (progenitor) cells is the primary endpoint, and may also serve as a surrogate endpoint for accelerated approval. Additional outcome measures include stability or increase in blood counts with no significant worsening in anemia, neutropenia or thrombocytopenia and peripheral blood and bone marrow genetic correction, as demonstrated by progressive increases in vector copy number (VCN) over the months subsequent to infusion.

Lucile Packard Childrens Hospital Stanford and Hospital Infantil Universitario Nio Jess are serving as the lead clinical sites and University of Minnesota is conducting centralized evaluation of bone marrow MMC-resistance and engaging in advisory activities for the global trial of RP-L102. RP-L102 was in-licensed from the Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas (CIEMAT), Centro de Investigacin Biomdica en Red de Enfermedades Raras (CIBERER), Instituto de Investigacin Sanitaria Fundacin Jimnez Daz (IIS-FJD) and Fundacion para la Investigacion Biomedica Hospital Infantil Universitario Nio Jesus (FIB-HIUNJ).

About Fanconi Anemia

Fanconi Anemia (FA) is a rare pediatric disease characterized by bone marrow failure, malformations and cancer predisposition. The primary cause of death among patients with FA is bone marrow failure, which typically occurs during the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT), when available, corrects the hematologic component of FA, but requires myeloablative conditioning, which is highly toxic for the patient. HSCT is frequently complicated by graft versus host disease and also increases the risk of solid tumors, particularly upper aerodigestive tract squamous cell carcinomas. Approximately 60-70% of patients with FA have a FANCA gene mutation, which encodes for a protein essential for DNA repair. Mutations in the FANCA gene leads to chromosomal breakage and increased sensitivity to oxidative and environmental stress. Chromosome fragility induced by DNA-alkylating agents such as mitomycin-C (MMC) or diepoxybutane (DEB) is the gold standard test for FA diagnosis. These assays can further differentiate FA patients from mosaic patients. Somatic mosaicism occurs when there is a spontaneous reversion mutation that can lead to a mixed chimerism of corrected and uncorrected bone marrow cells leading to stabilization or correction of an FA patients blood counts in the absence of any administered therapy. Somatic mosaicism provides strong rationale for the development of FA gene therapy and demonstrates the selective advantage of gene-corrected hematopoietic cells in FA1.

1Soulier, J.,et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105: 1329-1336

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed November 8, 2019. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005080/en/

Read more:
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia - BioSpace

Bone Marrow Stem Cells Comments Off on Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia – BioSpace | December 6th, 2019

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science

Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (Novadip or the company), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series of presentations at the 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) taking place in Marseille, France, from 4-7 December 2019.

Dr Denis Dufrane, Chief Scientific Officer and co-founder, Novadip, commented: The findings that will be presented at IFATS highlight the capabilities of Novadips 3-dimensional, scaffold-free extracellular matrix (ECM) technology platform utilizing adipose-derived stem cells (ASCs) to generate product candidates to address critical size bone and skin reconstruction, as well as our manufacturing capabilities and expertise. We look forward to progressing our clinical programmes and generating further data in support of our unique platform as we look to address hard and soft tissue reconstruction for patients who have limited or no treatment options.

Novadip will deliver five oral presentations and one video presentation. Details of the presentations and short summaries are below.

Genetic stability assessment in bone tissue-engineered productsCline Pierard, oral presentation #8 (abstract 1395), 5 December 2019, 8:38 am CET

The presentation will discuss the different analytical approaches to predict the genetic behavior over the entirety of the manufacturing process for the companys product candidates for bone reconstruction.

A scaffold-free graft for large critical size bone defect: preclinical evidence to clinical proof of conceptSophie Veriter, video presentation #V5 (abstract 1363), 5 December 2019, 2:48 pm CET

The session will discuss how the scaffold-free 3D-graft (comprised of ASCs) plays a major role promoting ASCs engraftment and to induce osteogenesis in a fibrotic environment and promote bone fusion in a critical-sized bone defect.

The in vivo immunogenicity of a human 3D scaffold-free tissue engineered product for bone reconstruction: a xenogenic modelGatan Thirion, oral presentation #30 (abstract 1382), 5 December 2019, 4:30 pm CET

Detail will be provided on how the human scaffold-free 3D approach, in a xenogenic model, can elicit a specific anti-human immune response but can maintain the potential of in vivo osteogenicity.

An allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro development to in vivo proof of conceptSophie Veriter, oral presentation #88 (abstract 1317), 6 December 2019, 5:50 pm CET

The presentation will discuss how the scaffold-free approach with the allogenic 3D-graft (derived from ASCs) demonstrated safety and efficacy in a stringent xenogenic model of hyperglycemic and ischemic deep-thickness wound.

Allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro characterization and in vivo biocompatibilityValrie Lebrun, oral presentation #90 (abstract 1341), 6 December 2019, 6:06 pm CET

The presentation will provide an overview on how the allogenic scaffold-free 3D-graft improves ASC bioactivity for the angiogenesis and in vivo remodeling by the specific ECM-proteins of wound healing.

Monitoring of cell culture conditions and early prediction of the quality of an osteogenic cell-based medicinal productAnas Namur, oral presentation #136 (abstract 1392), 7 December 2019, 2:44 pm CET

The session will describe how cellular metabolism was studied throughout the companys manufacturing process to better understand the physiology of the proliferative and differentiated cells and subsequently develop predictive tests focused on critical attributes of the final product.

To view the full abstracts, please follow this link.

The full list of abstracts can be found here. Further information on IFATS is available here.

- Ends -

Notes to editors

Novadip Biosciences

Novadip Biosciences is a clinical stage biopharmaceutical company leveraging its unique 3D tissue regeneration technology platform to generate multiple product candidates to address hard and soft tissue reconstruction for patients who have limited or no treatment options. The companys proprietary 3M3 platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly-specific growth factors and miRNA to mimic the physiology of natural healing and creates a range of products that address specific challenges in tissue regeneration. Novadips initial focus is on critical size bone reconstruction and its lead program is in development for a rare pediatric orthopedic disease. The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects. For more information, visit http://www.novadip.com .

For further information, please contact:

Novadip Biosciences

Jeff Abbey

Chief Executive Officer

+32 (10) 779 220

info@novadip.com

For media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Angela Gray

+44 (0) 20 3709 5700

novadip@consilium-comms.com

Read the rest here:
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science - GlobeNewswire

Skin Stem Cells Comments Off on Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science – GlobeNewswire | December 5th, 2019

Photo: Courtesy of the Retailer

Some of the best things in life take a month before you can reap their full benefits. Like Advent calendars, or Augustinus Baders The Cream.

It takes between 30 and 40 days for skin cells to turn over, so using any new beauty product requires patience, not to mention compliance. It can be hard to wait that long, but for this cream, its worth it. Just ask Kate Bosworth, who says, It is truly the ONE product I cant live without. Or L.A. beauty expert Cassandra Gray, who puts it more succinctly: I look younger. Thats the easiest way to sell it. Or the Cuts own Kathleen Hou, who has called it the secret to rich-person skin.

The cream is fueled by a cocktail of active ingredients that includes vitamins, natural amino acids, and a bunch of allegedly miraculous synthesized molecules referred to as Trigger Factor Complex 8. The latter was formulated by a professor of applied stem cell biology at the University of Leipzig, who was looking for solutions to help burn survivors heal faster. Turned out, TFC8 kicks off the regeneration process within stem cells, enabling them to repair fine lines, dark spots, redness, and uneven tone and texture.

At $265, this product is not cheap. But it would be a great gift for someone you really love, who really loves skin care. Just make sure to check in with them 30 to 40 days later to hear what they think.

Augustinus Bader The Cream

If you buy something through our links,New Yorkmay earn an affiliate commission.

Get the Cut newsletter delivered daily

Excerpt from:
Gift of the Day: A Cream That Will Give You Rich Person Skin - The Cut

Skin Stem Cells Comments Off on Gift of the Day: A Cream That Will Give You Rich Person Skin – The Cut | December 5th, 2019

RELATED: This brand new anti-ageing treatment is a game-changer

The neck is a delicate area thats easy to overlook, but it plays a big role in giving our face an attractive shape and profile. Over time, the skin may weaken from sun damage, dryness, and stress making us look much older. This is where firming neck creams come in handy! Here are some important active ingredients to look for in anti-aging products:

These products are packed with anti-wrinkle chemicals that tighten problem areas with regular use. Simply apply it with gentle motions after a shower and work it into your skin until fully absorbed. Pair it with your trusted eye cream and your skin will be thanking you!

If youre worried about the price, you can rest easy! Weve made sure to include a few budget options in our list for the savvy consumer.

Pros & Cons: This cream is made with organic ingredients and collagen to give your skin a supple glow! The downside is that it can be hard to find local stocks since its made in China.

Price: $AUD46.30

Buy It On: eBay

Pros & Cons: The combination of Hyaluronic Acid and creatine work together with Q10 coenzymes to regenerate new skin cells. A fair warning: some customers dont enjoy how the yellow colour of the pearls that stick to the skin.

Price: $AUD17.99

Buy It On: Amazon

Pros & Cons: This cream is made with aloe vera and Hyaluronic Acid, perfect for refining stubborn lines, wrinkles, and pigmentation on the neck. However, some people dont enjoy the grainy texture of the cream.

Price: $AUD52

Buy It On: Brickell Mens Products

Pros & Cons: Harnessing natures powerful vitamins, this cream uses botanical extracts to purge your skin of impurities. It works best for medium to dry skin, but could cause oily skin to break out.

Price: $AUD24.95

Buy It On: Swiss

Pros & Cons: This rich night cream is infused with Hyaluronic Acid and Retinol to replenish dull skin. It has lots of rave reviews for boasting visible results within a week, but the smell might be a little intense for some people.

Price: $AUD24.49

Buy It On: Amazon

Pros & Cons: Made with rosehip, olive, green coffee, and quinoa; this non-toxic, vegetarian cream brings out the best in your skin. But it may take a while to see results since it contains mild ingredients.

Price: $AUD16.95

Buy It On: Ebay

Pros & Cons: South Beach Skincare combines Vitamin C and Hyaluronic Acid with Retinol to create a paraben-free cream for all skin aging problems. Although its quite pricey, customers believe its worth every dollar!

Price: $AUD189

Buy It On: Life Cell Skin

Pros & Cons: This fragrance-free night cream evens out discolouration to give you a healthy glow, minimising stubborn imperfections with vitamins and minerals. Use it sparingly at night to avoid feeling greasy.

Price: $AUD20.99

Buy It On: Chemist Warehouse

Pros & Cons: Made with collagen and aloe vera, this cream repairs, hydrates, and protects your skin all day and night. Its the cheapest option available, so some customers think its too good to be true!

Price: $AUD5.26

Buy It: Ebay

Pros & Cons: Enriched with sunflower and green seaweed extracts, this light cream is easily absorbed by the skin for fast-acting results. Its great for all skin types, but some claim that they changed their formula recently.

Price: $AUD100

Buy It: Clarins

Pros & Cons: This cold cream works wonders on dry, flaky skin! Infused with organic Manuka honey from New Zealand, it locks moisture in to reduce pores and wrinkles. Apply sparingly to avoid getting sticky!

Price: $AUD40

Buy It On: Woolworths

Pros & Cons: Proven to be one of the top choices for middle-aged women, this cream uses Idebenone technology to target and repair areas damaged from harsh chemicals. Its quite costly, but it totally works!

Price: $AUD140

Buy It On: Myer

Pros & Cons: This cream is clinically-proven to fight saggy skin, discolouration, and visible signs of aging with amino acids and stem cell extracts. Just take it easy with application because the scent can be a bit overpowering.

Price: $AUD69.95

Buy It: NeoStrata

Pros & Cons: This tiny jar of plastic surgeon-approved cream is jam-packed with collagen, niacin, and complex amino acids. Its considered the holy grail for restoring the necks elastic texture, but it tends to run out fast!

Price: $AUD68

Buy It On: Sephora

Getting yourself a neck lift doesnt have to be drastic! Its all about keeping yourself moisturised and protected so you can look and feel younger at any age. Its time to get your cream on!

RELATED: Why the world can't stop talking about jade rollers

See more here:
15 Best Neck Creams (That Actually Work) - New Idea

Skin Stem Cells Comments Off on 15 Best Neck Creams (That Actually Work) – New Idea | December 5th, 2019

Transitional beauty can be a challenge. With shifting temperatures and weather, our hair and skin can feel dried out and dull, leaving our overall look (and feel) a little less than. But never fret, beauty babes! Ahead we've got our favorite new finds to keep you hydrated, moisturized, and looking luminous as heck all winter long and beyond!

Each & Every Worry-Free Deodorant ($15): Calling all sweaty Betty's, this 'Everlane of deodorants' is 2019's all-natural answer to your stinky woes. Made without aluminum, parabens, synthetic fragrances, gluten (yes, that's a thing), or baking soda, this cruelty-free stick comes in eight fab fragrances to keep you feeling dry and smelling fresh all day long.

On All Eyes On Me ($28): Instantly lift and cool those puffy, morning-after eyes with these slip-free eye gels. Packed with the good stuff like vitamin C, cucumber, and arnica and none of the bad, this travel-friendly 5-pack is ideal for your upcoming holiday adventures.

Kiehl's Avocado Nourishing Hydrating Mask ($45): What's better than avocado toast? Almost nothing. But this ultra-nourishing face mask is a close second. Rich and creamy, this fragrance-free formula takes just 15 minutes to give you the full, moisturized effects.

Maria Nila Silver Shampoo ($27): Summer may be gone, but your bright blonde doesn't have to go anywhere. Violet pigment and blackberry extract are the secrets to this 100% vegan and Swedish-made shampoo that's formulated to make your golden locks shine their lightest and brightest.

Alfie Firming Facial Serum ($64): Buh-bye pesky wrinkles! This serum does it all with the help of a few friends. Hyaluronic Acid, plant stem cells, and organic CBD are blended to firm up your face, hydrate lost moisture, improve blood flow, and reduce tension.

Kitsch Dalmatian Jasper Crystal Facial Roller ($24): ICYMI, gemstone rollers are all the rage right now, and we can see why. This Jasper beaut will gently massage away tension and stress to reduce wrinkles and help circulate blood.

Save Me From Chemical Conflict Tip To Hair Reboot ($78): Is your hair broken and therefore your life feels a little broken, too? Repair bleach damage and overprocessed locks with a scalp and hair treatment we can't stop raving about. Your radiant reboot begins NOW.

Milo New York Amber Fort Elixir Oud ($62+): A little facial oil can go a long way, especially when it's packed with vitamin C, alpha hydroxy acid, and Indian pink lotus flower. Brighter, smoother, more luminous skincare is here.

UMA Oils Flawlessly Firming Neck, Chest & Decolletage Serum ($105): Your skin deserves to feel smooth and firm no matter how old of a millennial you happen to be. Worth the extra buck, this antioxidant-rich serum is fast-absorbing and gives a more ageless appearance to your most delicate areas.

Tweezerman Lash Assist ($18): Lash on, lash off. From the pros who brought us a really good brow tweeze comes a one and done for your fake lashes. Seamlessly and precisely apply either individual or strip lashes for that glam effect you've always wanted sans stress!

Verb Curl Kit ($80): Calling all curly gals! This four-part kit is just what your locks will love. Clean, hydrate, restore, and define and keep those curls lookin' and feelin' healthy year-round.

RELATED: These Are the Best Everyday Face Sunscreens of 2019

Brit + Co may at times use affiliate links to promote products sold by others, but always offers genuine editorial recommendations.

Read the original:
Say Hello to Hydration With These Winter Beauty Essentials - Brit + Co

Skin Stem Cells Comments Off on Say Hello to Hydration With These Winter Beauty Essentials – Brit + Co | December 5th, 2019

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Continue reading here:
Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror

Skin Stem Cells Comments Off on Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror | December 5th, 2019

Washington (AFP)

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

- Cures -

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

- Bioterrorism -

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

2019 AFP

See more here:
2019: the year gene therapy came of age - FRANCE 24

Bone Marrow Stem Cells Comments Off on 2019: the year gene therapy came of age – FRANCE 24 | December 5th, 2019

A new business intelligence report released by Garner Insights with title Global Stem Cell Therapy Market Research Report 2019 that targets and provides comprehensive market analysis with prospects to 2024. The analysts of the study have garnered extensive research methodologies and data sources (i.e. Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

Get a Sample PDF Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#request-sample

Some of key competitors or manufacturers included in the study are: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix),

If you are involved in the Global Stem Cell Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports, we can provide customization according to your requirement.

Market Segment by Type, covers: Autologous, Allogeneic

Market Segment by Applications, can be divided into: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others,

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

What are the affecting elements that are made reference to in the report?

Market Scenario:The report further highlights the development trends in the global Stem Cell Therapy market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Key Market Highlights:The Stem Cell Therapy report gives a top to bottom examination on a portion of the key elements, involving income, cost, limit, limit usage rate, creation, generation rate, utilization, import/send out, supply/request, net, piece of the pie, CAGR, and gross edge. Furthermore, the report shows a far reaching investigation of the market development factors and their most recent patterns, alongside important market fragments and sub-portions.

Analytical Tools:The Global Stem Cell Therapy Market report incorporates the decisively examined and assessed information of the significant market members and their market scope utilizing various investigative devices. The diagnostic apparatuses incorporate Porters five powers examination, SWOT investigation, achievability study, and venture return investigation, which have been utilized to consider the development of the key players working in the market.

Get Discount on this Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#discount

Some of the Points cover in Global Stem Cell Therapy Market Research Report is:

Chapter 1: Overview of Global Stem Cell Therapy Market (2019-2024) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2019 and 2024 Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure. Continued

The main points which are answered and covered in this Report are-

What will be the total Stem Cell Therapy Market in the coming years till 2024?What will be the key factors which will be overall affecting the industry?What are the various challenges addressed?Which are the major companies included?

Thank You For Visiting Our Report : you can likewise get singular part astute segment or locale insightful report form like Asia, United States, Europe.

View Full Report@ https://garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#description

See the original post here:
As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types...

Bone Marrow Stem Cells Comments Off on As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types… | December 5th, 2019

The global bone marrow aspirate concentrates market was valued around US$ 130.0 Mn in 2016 is anticipated to register a stable CAGR of over 5.0% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled Bone Marrow Aspirate Concentrates Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20172025.

Growth of the global bone marrow aspirate concentrates market is driven by increased prevalence of and incidences of orthopedic diseases, and sports injuries, along with high growth of the cosmetic surgery industry and increasing applications of the BMAC products in the cosmetic and orthopedic surgeries. The bone marrow aspirate concentrates market in Asia Pacific is expanding with a high potential to grow registering a CAGR above 6.0% on the backdrop of unmet clinical needs, rising geriatric population, large patient pool, favorable government regulations, development in health care sector, and increased focus on research and developmental activities.

Request a PDF Sample of Bone Marrow Aspirate Concentrates Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40451

Increase in incidences of Osteoarthritis on the backdrop of rising geriatric population to drive market growth

According to a collaborative survey conducted by the United Nations and the World Health Organization, 1.2 billion people in China are suffering from OA, of which more than 55% are aged 60 years or above. On the backdrop of such a huge patient base, there has been several developments in the field orthopedic surgery. Bone marrow-derived stem cell treatment is considered a promising and advanced therapy. It reduces the injury healing time in orthopedic diseases to five to six weeks from four to six months in case of surgery.

Reduction in the healing time is a factor likely to propel the Bone Marrow Aspirate Concentrates market during the forecast period. However, pain associated with the treatment, lack of product approval, and preference for alternative treatments are negatively affecting the market growth. Moreover, high investments in R&D and clinical trials, slow approval processes entailing sunken costs, and marginal returns on investment (RoI) for stakeholders are primary concerns faced by manufacturer further hampering growth of the market.

Rise in the Number of BMAC Assisted Procedures to Boost Growth of Bone Marrow Aspirate Concentrates Accessories Segment

The product type segment is fragmented into bone marrow aspirate concentrates systems and bone marrow aspirate concentrates accessories. The bone marrow aspirate concentrates accessories segment is anticipated to carry major share of the market on the backdrop of rise in number of BMAC assisted procedures. Cell therapies have been used extensively over the past decade for a variety of medical applications to restore cellular function and enhance quality of life. Owing to the differentiation property, stem cells are being used for repair and regeneration of bone. Moreover, increase in awareness about hygiene and risk of cross-contamination in developing countries such as Brazil, China and India are expected to increase the use of single-use Jamshidi needles for bone marrow stem cell procedures. This is likely to fuel the growth of the accessories segment in the near future.

Request for a Discount on Bone Marrow Aspirate Concentrates Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40451

Orthopedic Surgery Application to Dominate the Global Bone Marrow Aspirate Concentrates Market

The application segment of global bone marrow aspirate concentrates market is divided into orthopedic surgery, wound healing, chronic pain, peripheral vascular disease, dermatology, and others applications. Of which, orthopedic surgery segment is anticipated to dominate the market owing to rising geriatric population, and surge in incidences of osteoarthritis around the globe.

The dermatology segment is anticipated to expand at the highest CAGR of over 6.0% during forecast period of 2017 to 2025 owing to current boom in the industry, increase in disposable income, and technological advancements in the market. The utilization of the regenerative ability of fibroblasts and keratinocytes from human skin has formed new ways to develop cell-based therapies for patients. Moreover, capacity of bone marrow derived extra-cutaneous cells is being researched for its plasticity in regenerating skin; it is likely to lead to the future growth of cell therapies in dermatology.

Rise in Healthcare Expenditure to Fuel Growth of Hospitals & Clinics End-user Segment

In terms of end-users, market is divided into hospitals & clinics, pharmaceutical & biotechnology companies, Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), and academic & research institutes. The hospitals & clinics segment dominated the bone marrow aspirate concentrates market in 2016. The trend is expected to continue during the forecast period. The hospitals & clinics segment is likely to be followed by the biotechnology & biopharmaceutical companies segment in terms of market share during the forecast period. The segment is anticipated to hold more than 8.0% of market share in 2016. Growth of the segment is attributed to increasing number of biotechnology companies and rising partnerships among the market players to expand global presence.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: [emailprotected]Website: http://www.transparencymarketresearch.comBlog: https://theglobalhealthnews.com/

The rest is here:
Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 - Drnewsindustry

Bone Marrow Stem Cells Comments Off on Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 – Drnewsindustry | December 5th, 2019